Objective
Our recent results on antitumor effects of carbohydrate mimotope peptides (CMP) suggest a possible role of carbohydrate reactive B cell subpopulations as cellular adjuvants. As an abundant alternative of dendritic cells, CD40-activated B cells can efficiently present specific antigens being expandable for several weeks. Some B cells can be sufficiently detrimental to warrant anti-B cell therapy in cancer. Other (mouse) B cell subsets (e.g. B1 and marginal zone (MZ) B cells) seem as effective as mature DC, including skewing the T cell to the desirable Th1 responses. Thus, B subpopulations deserve scrutiny as the optimal antigen presenting cells. We hypothesize that CMP target carbohydrate reactive B cells, which present the collinear T cell epitopes to auxiliary T cells, create an environment conducive to epitope spreading to glycoprotein tumor antigens. The major mature B cell subpopualtions in the mouse are B2 follicular cells, MZ B cells, as well as B1a and B1b peritoneal B cells. The translation of a B cell strategy to the clinic is hindered by lack of straightforward functional homologies between mouse and human B cell subsets. Therefore, we propose to study the potential of ex vivo expanded human B cell subpopulations to present CMP and induce an appropriate cytokine environment for the development of anti-tumor CTL responses in comparison to the mouse system. To this end we propose to compare the phenotype and antigen presenting properties of mouse and human CMP specific B cells. These studies will allow for the design of therapeutic approaches based on ex vivo expansion of phenotypically similar B cells and using them for active immunotherapy of cancer after loading with appropriate antigens. The relevance of the CMP specific system to a bulk population of the same phenotype stems from the capacity of B cells to present antigens targeted nonspecifically for instance to CD19.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- natural sciences biological sciences biochemistry biomolecules carbohydrates
- medical and health sciences clinical medicine oncology
- medical and health sciences basic medicine immunology immunotherapy
- medical and health sciences medical biotechnology cells technologies
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2009-RG
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
1113 Sofia
Bulgaria
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.